
Novartis experimental prostate cancer drug gets FDA breakthrough designation
Fox News
Novartis announced on Wednesday that the FDA granted Breakthrough Therapy designation to an experimental therapy that targets advanced castration-resistant prostate cancer.
According to the company, the Phase 3 VISION study demonstrated that the drug significantly improved overall survival and radiographic progression-free survival for men with progressive PSMA-positive mCRPC. Castrate-resistant prostate cancer is diagnosed when the disease keeps growing even though the amount of testosterone in the body has been reduced to very low levels. Cancer may also be found in other parts of the body. Current treatment goals are to control symptoms and slow progress.More Related News